CO2021013496A2 - Composiciones y métodos para tratar el cáncer - Google Patents
Composiciones y métodos para tratar el cáncerInfo
- Publication number
- CO2021013496A2 CO2021013496A2 CONC2021/0013496A CO2021013496A CO2021013496A2 CO 2021013496 A2 CO2021013496 A2 CO 2021013496A2 CO 2021013496 A CO2021013496 A CO 2021013496A CO 2021013496 A2 CO2021013496 A2 CO 2021013496A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- egfr
- compositions
- treating cancer
- present disclosure
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 3
- 208000005017 glioblastoma Diseases 0.000 abstract 2
- 230000004153 glucose metabolism Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819322P | 2019-03-15 | 2019-03-15 | |
| US201962904241P | 2019-09-23 | 2019-09-23 | |
| PCT/US2020/022743 WO2020190765A2 (en) | 2019-03-15 | 2020-03-13 | Compositions and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021013496A2 true CO2021013496A2 (es) | 2022-01-17 |
Family
ID=72521289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0013496A CO2021013496A2 (es) | 2019-03-15 | 2021-10-11 | Composiciones y métodos para tratar el cáncer |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11377451B2 (https=) |
| EP (1) | EP3938354A4 (https=) |
| JP (2) | JP7474269B2 (https=) |
| KR (1) | KR102809395B1 (https=) |
| CN (2) | CN115215808B (https=) |
| AU (1) | AU2020241703B2 (https=) |
| BR (1) | BR112021018295A2 (https=) |
| CA (1) | CA3133688A1 (https=) |
| CL (1) | CL2021002409A1 (https=) |
| CO (1) | CO2021013496A2 (https=) |
| CR (1) | CR20210498A (https=) |
| IL (1) | IL286350A (https=) |
| MX (1) | MX2021011272A (https=) |
| PH (1) | PH12021552208A1 (https=) |
| SA (1) | SA521430328B1 (https=) |
| SG (1) | SG11202109662YA (https=) |
| WO (1) | WO2020190765A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| KR102809395B1 (ko) | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| WO2022061201A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022155311A1 (en) * | 2021-01-14 | 2022-07-21 | The Regents Of The University Of California | Methods and systems for analysis of drug target engagement and treatment of cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| US20240165132A1 (en) * | 2021-05-12 | 2024-05-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN113307799B (zh) * | 2021-05-21 | 2022-07-19 | 大连医科大学 | 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用 |
| EP4405360A4 (en) * | 2021-09-23 | 2025-08-20 | Erasca Inc | POLYMORPHIC FORMS OF EGFR INHIBITOR |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
| WO2024081447A1 (en) * | 2022-10-14 | 2024-04-18 | The Regents Of The University Of California | Egfr inhibitors for treating lung cancer |
| WO2024102177A1 (en) * | 2022-11-08 | 2024-05-16 | The Regents Of The University Of California | Combination therapies for the treatment of brain cancer |
| WO2025117739A1 (en) * | 2023-11-27 | 2025-06-05 | Erasca, Inc. | Compositions and methods for treating cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법 |
| CN1854130B (zh) | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| WO2008046242A1 (fr) | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
| WO2011035540A1 (zh) | 2009-09-28 | 2011-03-31 | 齐鲁制药有限公司 | 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物 |
| ITPD20110091A1 (it) | 2011-03-24 | 2012-09-25 | Univ Padova | Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico. |
| NZ732511A (en) * | 2014-12-15 | 2018-11-30 | Univ Michigan Regents | Small molecule inhibitors of egfr and pi3k |
| CA2974442A1 (en) * | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
| CN105017163A (zh) | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| US10473255B2 (en) | 2015-12-29 | 2019-11-12 | Ge-Hitachi Nuclear Energy Americas Llc | Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device |
| AU2017204973A1 (en) | 2016-01-06 | 2018-07-12 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
| CN106432202B (zh) | 2016-09-22 | 2019-04-02 | 郑州大学第一附属医院 | 喹唑啉类衍生物及其应用 |
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| KR102809395B1 (ko) | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| WO2022061201A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| US20240058340A1 (en) | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| EP4405360A4 (en) * | 2021-09-23 | 2025-08-20 | Erasca Inc | POLYMORPHIC FORMS OF EGFR INHIBITOR |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
-
2020
- 2020-03-13 KR KR1020217032873A patent/KR102809395B1/ko active Active
- 2020-03-13 BR BR112021018295A patent/BR112021018295A2/pt unknown
- 2020-03-13 MX MX2021011272A patent/MX2021011272A/es unknown
- 2020-03-13 CN CN202210268803.XA patent/CN115215808B/zh active Active
- 2020-03-13 WO PCT/US2020/022743 patent/WO2020190765A2/en not_active Ceased
- 2020-03-13 EP EP20773177.9A patent/EP3938354A4/en active Pending
- 2020-03-13 SG SG11202109662Y patent/SG11202109662YA/en unknown
- 2020-03-13 AU AU2020241703A patent/AU2020241703B2/en active Active
- 2020-03-13 CA CA3133688A patent/CA3133688A1/en active Pending
- 2020-03-13 JP JP2021555445A patent/JP7474269B2/ja active Active
- 2020-03-13 CN CN202080034742.XA patent/CN113811528A/zh active Pending
- 2020-03-13 CR CR20210498A patent/CR20210498A/es unknown
- 2020-03-13 PH PH1/2021/552208A patent/PH12021552208A1/en unknown
-
2021
- 2021-09-13 IL IL286350A patent/IL286350A/en unknown
- 2021-09-14 US US17/475,144 patent/US11377451B2/en active Active
- 2021-09-15 CL CL2021002409A patent/CL2021002409A1/es unknown
- 2021-09-15 SA SA521430328A patent/SA521430328B1/ar unknown
- 2021-10-11 CO CONC2021/0013496A patent/CO2021013496A2/es unknown
-
2022
- 2022-06-29 US US17/853,573 patent/US20230115366A1/en not_active Abandoned
-
2024
- 2024-04-12 JP JP2024064400A patent/JP7789832B2/ja active Active
- 2024-06-12 US US18/741,322 patent/US20250145634A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3133688A1 (en) | 2020-09-24 |
| CL2021002409A1 (es) | 2022-06-17 |
| CN115215808A (zh) | 2022-10-21 |
| EP3938354A2 (en) | 2022-01-19 |
| SG11202109662YA (en) | 2021-10-28 |
| AU2020241703A1 (en) | 2021-10-14 |
| US20220064177A1 (en) | 2022-03-03 |
| SA521430328B1 (ar) | 2024-03-28 |
| PH12021552208A1 (en) | 2022-05-30 |
| WO2020190765A3 (en) | 2020-11-26 |
| JP7789832B2 (ja) | 2025-12-22 |
| CN115215808B (zh) | 2025-04-18 |
| JP2024102094A (ja) | 2024-07-30 |
| AU2020241703B2 (en) | 2026-02-05 |
| US11377451B2 (en) | 2022-07-05 |
| IL286350A (en) | 2021-10-31 |
| KR20210151820A (ko) | 2021-12-14 |
| JP2022526266A (ja) | 2022-05-24 |
| WO2020190765A2 (en) | 2020-09-24 |
| KR102809395B1 (ko) | 2025-05-16 |
| CR20210498A (es) | 2022-01-11 |
| US20250145634A1 (en) | 2025-05-08 |
| US20230115366A1 (en) | 2023-04-13 |
| EP3938354A4 (en) | 2022-12-28 |
| JP7474269B2 (ja) | 2024-04-24 |
| CN113811528A (zh) | 2021-12-17 |
| BR112021018295A2 (pt) | 2021-11-23 |
| MX2021011272A (es) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021013496A2 (es) | Composiciones y métodos para tratar el cáncer | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| MX2023006145A (es) | Inhibidores de prmt5 novedosos. | |
| ECSP19043254A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2 | |
| MX2023004518A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
| MX2019011221A (es) | Terapia de combinacion para el tratamiento o prevencion de tumores. | |
| AR054566A1 (es) | Tratamientoombinado de los tumores que expresan el her | |
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| TNSN08375A1 (en) | Quinazolines for pdk1 inhibition | |
| MX2016016115A (es) | Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr). | |
| MX373584B (es) | Tratamiento de cánceres utilizando moduladores de la isoforma pi3 cinasa. | |
| MX394252B (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf | |
| EP4512480A3 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| BR112015006176A8 (pt) | método de tratamento de câncer em um indivíduo com necessidade de tratamento | |
| NZ729643A (en) | Combination therapy for treating cancer | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| EP4389225A3 (en) | Cancer treatments using combinations of type 2 mek and erk inhibitors | |
| JOP20200242A1 (ar) | مركبات البلاديينوليد واستخداماتها | |
| BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
| MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| MX2023008375A (es) | Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas. | |
| Joensuu et al. | A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer | |
| MX2015004703A (es) | Composiciones cancerigenas inyectables. |